Peritoneal Cancer – Pipeline Review, H2 2019

Global Markets Direct’s, ‘Peritoneal Cancer – Pipeline Review, H2 2019’, provides an overview of the Peritoneal Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Peritoneal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peritoneal Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Peritoneal Cancer

– The report reviews pipeline therapeutics for Peritoneal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Peritoneal Cancer therapeutics and enlists all their major and minor projects

– The report assesses Peritoneal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Peritoneal Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Peritoneal Cancer

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Peritoneal Cancer pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AB Science SA

AbbVie Inc

Advenchen Laboratories LLC

AIM ImmunoTech Inc

AiVita Biomedical Inc

Aldeyra Therapeutics Inc

Altor Bioscience LLC

ALX Oncology Inc

Anew Oncology Inc

Apexigen Inc

Apotex Inc

Aravive Inc

Arrien Pharmaceuticals LLC

Ascend Biopharmaceuticals Ltd

Ascenta Therapeutics Inc

Astellas Pharma Inc

Astex Pharmaceuticals Inc

AstraZeneca Plc

Atara Biotherapeutics Inc

Bayer AG

BeiGene Ltd

Bio-Path Holdings Inc

BioIntegrator Ltd

Boehringer Ingelheim International GmbH

Boston Biomedical Inc

Bristol-Myers Squibb Co

Celldex Therapeutics Inc

Celsion Corp

CerRx Inc

Chipscreen Biosciences Ltd

Clover Biopharmaceuticals

Clovis Oncology Inc

Context Therapeutics LLC

Corcept Therapeutics Inc

Cotinga Pharmaceuticals Inc

Cristal Therapeutics BV

CytomX Therapeutics Inc

Daiichi Sankyo Co Ltd

EirGenix Inc

Eisai Co Ltd

Eli Lilly and Co

EpiThany Inc

Epizyme Inc

Esperance Pharmaceuticals Inc

Exelixis Inc

F. Hoffmann-La Roche Ltd

Fate Therapeutics Inc

Forty Seven Inc

Gene Techno Science Co Ltd

Genelux Corp

Genentech Inc

Genmab A/S

GlaxoSmithKline Plc

Gradalis Inc

I-Mab Biopharma Co Ltd

ImmunoGen Inc

IMPACT Therapeutics Inc

IMV Inc

Incyte Corp

Innate Pharma SA

InSight Biopharmaceuticals Ltd

Ionic Pharmaceuticals LLC

Jiangsu Hengrui Medicine Co Ltd

Johnson & Johnson

Juno Therapeutics Inc

Karyopharm Therapeutics Inc

Kazia Therapeutics Ltd

Kyowa Kirin Co Ltd

Leap Therapeutics Inc

Lidds AB

Lipac Oncology LLC

Lokon Pharma AB

MabVax Therapeutics Holdings Inc

Mateon Therapeutics Inc

MaxCyte Inc

Merck & Co Inc

Merck KGaA

Mersana Therapeutics Inc

Millennium Pharmaceuticals Inc

Morphotek Inc

Morvus Technology Ltd

MUCPharm Pty Ltd

Mycenax Biotech Inc

Neon Therapeutics Inc

Neovii Pharmaceuticals AG

NewLink Genetics Corp

Northlake International LLC

Novartis AG

NuCana Plc

Oasmia Pharmaceutical AB

OBI Pharma Inc

Oncoinvent AS

Oncolix Inc

Oncolytics Biotech Inc

OncoMed Pharmaceuticals Inc

OncoQuest Inc

Oncovir Inc

Ono Pharmaceutical Co Ltd

Orano Med LLC

Pfizer Inc

Pharma Mar SA

PharmAbcine Inc

Plexxikon Inc

Polaris Pharmaceuticals Inc

Precigen Inc

Prescient Therapeutics Ltd

Prestige BioPharma Pte Ltd

PsiOxus Therapeutics Ltd

PTC Therapeutics Inc

R-Pharm US LLC

Regeneron Pharmaceuticals Inc

Rgenix Inc

Richter Gedeon Nyrt

Rigel Pharmaceuticals Inc

Samyang Holdings Corp

Sanofi

Sanofi Pasteur SA

SELLAS Life Sciences Group Inc

Shenzen SiBiono GeneTech Co Ltd

Siam Bioscience Co Ltd

Soricimed Biopharma Inc

Sotio AS

Sun Pharma Advanced Research Company Ltd

Sutro Biopharma Inc

Syndax Pharmaceuticals Inc

Synermore Biologics Co Ltd

Tara Immuno-Oncology Therapeutics LLC

Targovax ASA

Transgene SA

Vascular Biogenics Ltd

Verastem Inc

Vyriad Inc

Xcovery Holding Company LLC

Xencor Inc

Y-mAbs Therapeutics Inc

Table of Contents

Table of Contents

Introduction

Peritoneal Cancer - Overview

Peritoneal Cancer - Therapeutics Development

Peritoneal Cancer - Therapeutics Assessment

Peritoneal Cancer - Companies Involved in Therapeutics Development

Peritoneal Cancer - Drug Profiles

Peritoneal Cancer - Dormant Projects

Peritoneal Cancer - Discontinued Products

Peritoneal Cancer - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Peritoneal Cancer, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..5), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..6), H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Products under Development by Companies, H2 2019 (Contd..4), H2 2019

Products under Development by Companies, H2 2019 (Contd..5), H2 2019

Products under Development by Companies, H2 2019 (Contd..6), H2 2019

Products under Development by Companies, H2 2019 (Contd..7), H2 2019

Products under Development by Companies, H2 2019 (Contd..8), H2 2019

Products under Development by Companies, H2 2019 (Contd..9), H2 2019

Products under Development by Companies, H2 2019 (Contd..10), H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019

Number of Products by Stage and Target, H2 2019 (Contd..3), H2 2019

Number of Products by Stage and Target, H2 2019 (Contd..4), H2 2019

Number of Products by Stage and Target, H2 2019 (Contd..5), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..3), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..4), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..5), H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Peritoneal Cancer – Pipeline by AB Science SA, H2 2019

Peritoneal Cancer – Pipeline by AbbVie Inc, H2 2019

Peritoneal Cancer – Pipeline by Advenchen Laboratories LLC, H2 2019

Peritoneal Cancer – Pipeline by AIM ImmunoTech Inc, H2 2019

Peritoneal Cancer – Pipeline by AiVita Biomedical Inc, H2 2019

Peritoneal Cancer – Pipeline by Aldeyra Therapeutics Inc, H2 2019

Peritoneal Cancer – Pipeline by Altor Bioscience LLC, H2 2019

Peritoneal Cancer – Pipeline by ALX Oncology Inc, H2 2019

Peritoneal Cancer – Pipeline by Anew Oncology Inc, H2 2019

Peritoneal Cancer – Pipeline by Apexigen Inc, H2 2019

Peritoneal Cancer – Pipeline by Apotex Inc, H2 2019

Peritoneal Cancer – Pipeline by Aravive Inc, H2 2019

Peritoneal Cancer – Pipeline by Arrien Pharmaceuticals LLC, H2 2019

Peritoneal Cancer – Pipeline by Ascend Biopharmaceuticals Ltd, H2 2019

List of Figures

List of Figures

Number of Products under Development for Peritoneal Cancer, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Number of Products by Top 10 Targets, H2 2019

Number of Products by Stage and Top 10 Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Top 10 Routes of Administration, H2 2019

Number of Products by Stage and Top 10 Routes of Administration, H2 2019

Number of Products by Top 10 Molecule Types, H2 2019

Number of Products by Stage and Top 10 Molecule Types, H2 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports